Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 30 05 2018
revised: 13 09 2018
accepted: 23 10 2018
pubmed: 6 11 2018
medline: 5 11 2019
entrez: 5 11 2018
Statut: ppublish

Résumé

Highly pathogenic viruses such as EBOV are a threat to routine laboratory workers. Inactivation procedures with Triton X-100 0.1% and/or heat are currently recommended, but have unknown effects on the accuracy of serological testing. Furthermore, virus inactivation by Triton X-100 0.1% was shown to be ineffective in serum. This study aimed to demonstrate virus inactivation in serum by Triton X-100 1% and maintained accuracy of serological testing. A panel of 19 serological tests was run on patient serum samples after treatment with Triton X-100 1%, 0.1%, and 0.1% + heat inactivation at 60°C for 1 h. Mean differences between measurements (bias) were calculated applying the Bland-Altman method. To determine effectiveness of virus inactivation, herpes simplex virus 1 (HSV-1) was spiked into medium containing 90% or 1% serum, and treated with Triton X-100 0.1% or 1%. Infectious titres were then determined on Vero cells. Serological measurements showed good agreement between controls and samples treated with Triton X-100 0.1% and 1%, with an estimated bias of 0.6 ± 9.2% (n = 258) and -0.1 ± 18.6% (n = 174), respectively. Discordant qualitative results were rare. Conversely, heat inactivation alone and combined with Triton X-100 0.1% triggered a bias of 17.5 ± 66.4% (n = 200) and 37.9 ± 79.8% (n = 160), respectively. Triton X-100 1% completely inactivated HSV-1 in 1% and 90% serum while Triton X-100 0.1% failed to do so in 90% serum. Unlike heat inactivation, Triton X-100 1% enabled accurate serological testing and completely inactivated HSV-1 in serum. This simple method could allow safe routine serological diagnostics in high-risk patients.

Identifiants

pubmed: 30391583
pii: S1198-743X(18)30721-3
doi: 10.1016/j.cmi.2018.10.016
pmc: PMC7128130
pii:
doi:

Substances chimiques

Octoxynol 9002-93-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

907.e7-907.e12

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Références

J Clin Virol. 2017 Jan;86:27-30
pubmed: 27912126
Biotechnol Bioeng. 2017 Apr;114(4):813-820
pubmed: 27800626
Transfusion. 2016 Jun;56(6):1384-93
pubmed: 27125447
Ann Clin Biochem. 1990 Nov;27 ( Pt 6):592-4
pubmed: 2080860
Clin Chem Lab Med. 2015 Nov;53(12):1967-73
pubmed: 26053010
J Clin Microbiol. 2015 Oct;53(10):3148-54
pubmed: 26179307
J Virol Methods. 1988 Dec;22(2-3):165-72
pubmed: 3146583
Science. 2014 Sep 12;345(6202):1369-72
pubmed: 25214632
J Clin Microbiol. 2015 Apr;53(4):1387-90
pubmed: 25631810
J Infect Dis. 2016 Oct 15;214(suppl 3):S218-S221
pubmed: 27571899
Virol J. 2010 Feb 18;7:40
pubmed: 20167059
Ann Clin Biochem. 2000 Nov;37 ( Pt 6):802-4
pubmed: 11085629
J Clin Microbiol. 1984 Sep;20(3):486-9
pubmed: 6490832
Lancet. 1985 Jan 26;1(8422):188-9
pubmed: 2857267
Emerg Infect Dis. 2016 Jul;22(7):1292-4
pubmed: 27070504
J Virol Methods. 2017 Dec;250:34-40
pubmed: 28941617
Clin Chem. 2004 May;50(5):944-6
pubmed: 15105356
J Infect Dis. 1998 Dec;178(6):1852-5
pubmed: 9815250
J Clin Microbiol. 2016 Oct;54(10):2521-9
pubmed: 27466385
Crit Rev Toxicol. 1996 May;26(3):335-64
pubmed: 8726166
Science. 2018 Mar 16;359(6381):1201-1202
pubmed: 29590055
MMWR Morb Mortal Wkly Rep. 1995 Jun 30;44(25):475-9
pubmed: 7783731
Antimicrob Agents Chemother. 1999 Feb;43(2):314-21
pubmed: 9925525
J Clin Pathol. 2016 Jul;69(7):637-42
pubmed: 26670745
Eur J Clin Microbiol Infect Dis. 1988 Aug;7(4):518-23
pubmed: 3141160
Curr Protoc Microbiol. 2005 Oct;Chapter 14:Unit 14E.1
pubmed: 18770556
Clin Infect Dis. 2018 Nov 13;67(11):1788-1795
pubmed: 30084955
Antiviral Res. 2001 Oct;52(1):25-32
pubmed: 11530185
J Infect Dis. 2017 Oct 17;216(7):859-866
pubmed: 28961947

Auteurs

M M Remy (MM)

Institute for Infectious Diseases, University of Bern, Bern CH-3001, Switzerland. Electronic address: Melissa.Remy@ifik.unibe.ch.

M Alfter (M)

Institute for Infectious Diseases, University of Bern, Bern CH-3001, Switzerland.

M-N Chiem (MN)

Institute for Infectious Diseases, University of Bern, Bern CH-3001, Switzerland.

M T Barbani (MT)

Institute for Infectious Diseases, University of Bern, Bern CH-3001, Switzerland.

O B Engler (OB)

Spiez Laboratory, Federal Office for Civil Protection, Spiez CH-3700, Switzerland.

F Suter-Riniker (F)

Institute for Infectious Diseases, University of Bern, Bern CH-3001, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH